Security Snapshot

CG Oncology, Inc. - Common Stock (CGON) Institutional Ownership

CUSIP: 156944100

13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

192

Shares (Excl. Options)

82,633,941

Price

$41.52

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
CGON on Nasdaq
Shares outstanding
76,566,375
Price per share
$67.68
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
82,633,941
Total reported value
$3,430,435,212
% of total 13F portfolios
0%
Share change
+1,329,905
Value change
+$57,920,734
Number of holders
192
Price from insider filings
$67.68
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CGON - CG Oncology, Inc. - Common Stock is tracked under CUSIP 156944100.
  • 192 institutions reported positions in Q4 2025.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 192 to 18 between Q4 2025 and Q1 2026.
  • Reported value moved from $3,430,435,212 to $11,448,171.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 192 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 156944100?
CUSIP 156944100 identifies CGON - CG Oncology, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of CG Oncology, Inc. - Common Stock (CGON) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Decheng Capital Global Life Sciences Fund IV, L.P. 8.4% $178,215,582 6,371,669 Xiangmin Cui 31 Dec 2024
WELLINGTON MANAGEMENT GROUP LLP 7.2% $222,054,738 5,512,779 Wellington Management Group LLP 30 Sep 2025
Longitude Capital Partners IV, LLC 6% $121,032,477 4,662,268 Patrick G. Enright 11 Sep 2025
Unique Diamond Investments Ltd 5.5% $117,791,208 4,211,341 SONG, Hong Fang 31 Dec 2024
FMR LLC 5.1% $100,262,786 3,856,261 FMR LLC 30 Jun 2025
TCG Crossover GP I, LLC 4.8% $102,655,662 3,670,206 TCG Crossover GP I, LLC 31 Mar 2025
Seven Fleet Capital Management LP 2% $62,145,313 1,542,833 Brian Liu 06 Oct 2025
Seven Fleet Partners LP 1.9% $39,333,320 1,515,151 Seven Fleet Partners LP 11 Sep 2025

As of 31 Dec 2025, 192 institutional investors reported holding 82,633,941 shares of CG Oncology, Inc. - Common Stock (CGON). This represents 108% of the company’s total 76,566,375 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CG Oncology, Inc. - Common Stock (CGON) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.5% 6,539,482 -0.57% 0% $271,519,293
Decheng Capital LLC 8.3% 6,371,669 0% 36% $264,551,697
WELLINGTON MANAGEMENT GROUP LLP 7.8% 5,999,790 +8.8% 0.04% $249,111,280
BlackRock, Inc. 6.3% 4,843,242 +5.6% 0% $201,091,408
FMR LLC 5.6% 4,298,173 +11% 0.01% $178,460,143
TCG Crossover Management, LLC 4.8% 3,670,206 0% 5% $152,386,953
PRICE T ROWE ASSOCIATES INC /MD/ 4.5% 3,443,144 +117% 0.02% $142,961,000
STATE STREET CORP 3.9% 2,996,695 +46% 0% $124,422,776
Foresite Capital Management VI LLC 2.9% 2,221,474 0% 28% $92,235,600
RTW INVESTMENTS, LP 2.6% 2,012,127 +18% 0.84% $83,543,513
UBS Group AG 2.5% 1,923,746 -9.5% 0.02% $79,873,935
BRAIDWELL LP 2.4% 1,870,571 -43% 2.5% $77,666,108
ALLIANCEBERNSTEIN L.P. 2.1% 1,613,425 -25% 0.02% $66,989,406
FRANKLIN RESOURCES INC 2% 1,561,574 +6.3% 0.02% $64,836,553
ORBIMED ADVISORS LLC 2% 1,516,550 -12% 1.3% $62,967,156
Seven Fleet Capital Management LP 2% 1,515,151 0% 43% $62,909,069
GEODE CAPITAL MANAGEMENT, LLC 2% 1,511,533 +2.6% 0% $62,772,944
Avidity Partners Management LP 1.9% 1,472,699 -8% 18% $61,146,462
DV Trading LLC 1.9% 1,439,393 0% 5.2% $59,763,597
Pictet Asset Management Holding SA 1.8% 1,349,527 +2.3% 0.05% $56,032,361
GOLDMAN SACHS GROUP INC 1.7% 1,324,603 -3.1% 0.01% $54,997,517
BANK OF AMERICA CORP /DE/ 1.6% 1,190,053 +59% 0% $49,411,001
ACORN CAPITAL ADVISORS, LLC 1.5% 1,131,501 0% 16% $46,979,903
Polar Capital Holdings Plc 1.4% 1,098,662 0% 0.21% $45,616,446
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 1.4% 1,090,894 +40% 0.01% $45,293,919

Institutional Holders of CG Oncology, Inc. - Common Stock (CGON) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 169,172 $11,448,171 +$945,452 $67.68 18
2025 Q4 82,633,941 $3,430,435,212 +$57,920,734 $41.52 192
2025 Q3 77,648,888 $3,127,517,509 +$92,134,469 $40.28 175
2025 Q2 75,914,566 $1,973,784,426 +$139,061,983 $26.00 161
2025 Q1 70,762,639 $1,735,652,621 +$98,334,837 $24.49 141
2024 Q4 66,057,386 $1,894,540,823 +$282,964,154 $28.68 137
2024 Q3 52,183,069 $1,962,909,867 +$277,213,171 $37.73 120
2024 Q2 43,274,514 $1,366,161,770 +$105,145,067 $31.57 109
2024 Q1 38,771,794 $1,702,050,758 +$1,700,470,138 $43.90 96